litlas
Log inCreate account

Roger B. Cohen

Active 1985–2025

106
Papers
24,317
Citations
66
h-index
101
i10-index

Citations

Citations per year for Roger B. Cohen1956: 1 citations1986: 9 citations1987: 16 citations1988: 10 citations1989: 3 citations1990: 6 citations1991: 3 citations1992: 7 citations1993: 3 citations1994: 2 citations1995: 6 citations1996: 2 citations1997: 1 citations1998: 3 citations1999: 5 citations2000: 18 citations2001: 29 citations2002: 35 citations2003: 37 citations2004: 35 citations2005: 36 citations2006: 62 citations2007: 104 citations2008: 146 citations2009: 180 citations2010: 207 citations2011: 207 citations2012: 195 citations2013: 208 citations2014: 186 citations2015: 155 citations2016: 147 citations2017: 151 citations2018: 152 citations2019: 784 citations2020: 962 citations2021: 923 citations2022: 732 citations2023: 562 citations2024: 733 citations2025: 414 citations2026: 6 citations1957–1985: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,045 citing papers, 28.2% of this breakdownChina: 1,262 citing papers, 11.7% of this breakdownItaly: 620 citing papers, 5.7% of this breakdownUnited Kingdom: 524 citing papers, 4.8% of this breakdownGermany: 522 citing papers, 4.8% of this breakdownFrance: 515 citing papers, 4.8% of this breakdownJapan: 391 citing papers, 3.6% of this breakdownSpain: 369 citing papers, 3.4% of this breakdownCanada: 353 citing papers, 3.3% of this breakdownNetherlands: 342 citing papers, 3.2% of this breakdownAustralia: 276 citing papers, 2.6% of this breakdownBelgium: 189 citing papers, 1.7% of this breakdown
0%28.2%Other 22.2%

Institutions

Fields

  • Medicine67%
  • Biochemistry, Genetics and Molecular Biology21.1%
  • Immunology and Microbiology8.8%
  • Engineering0.5%
  • Computer Science0.3%
  • Chemistry0.3%
  • Other2%

Topics

  • Cancer Immunotherapy and Biomarkers8.2%
  • Head and Neck Cancer Studies5.4%
  • Lung Cancer Treatments and Mutations5.1%
  • Immune Cell Function and Interaction3.4%
  • Cancer Genomics and Diagnostics2.9%
  • CAR-T cell therapy research2.7%
  • Other72.3%

Coauthors

All papers

Open in search
  1. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

    Authors: Pascale André, Caroline Denis, Caroline Soulas, Clarisse Bourbon-Caillet, Julie Lopez, Thomas Arnoux, Mathieu Bléry, Cécile Bonnafous, Laurent Gauthier, Ariane Morel, Benjamín Rossi, Romain Remark, Violette Breso, Elodie Bonnet, Guillaume Habif, Sophie Guia, Ana I. Lalanne, Caroline Hoffmann, Olivier Lantz, Jérôme Fayette, Agnès Boyer-Chammard, Robert Zerbib, P. Dodion, Hormas Ghadially, Maria Jure‐Kunkel, Yannis Morel, Ronald Herbst, Émilie Narni-Mancinelli, Roger B. Cohen, Éric Vivier - Cell 2018 cited by 1,212

  2. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

    Authors: Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul, Albiruni R. Abdul Razak, Jaafar Bennouna, Jean‐Charles Soria, Hope S. Rugo, Roger B. Cohen, Bert H. O’Neil, Janice M. Mehnert, Juanita Lopez, Toshihiko Doi, Emilie M.J. van Brummelen, Răzvan Cristescu, Ping Yang, Kenneth Emancipator, Karen Stein, Mark Ayers, Andrew K. Joe, Jared Lunceford - Journal of Clinical Oncology 2018 cited by 992

  3. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

    Authors: James A. Bonner, Paul M. Harari, J. Giralt, N. Azarnia, Dong M. Shin, Roger B. Cohen, Christopher U. Jones, Ranjan Sur, David Raben, Jacek Jassem, Roger Ove, Merrill S. Kies, José Baselga, Hagop Youssoufian, Nadia Amellal, Eric K. Rowinsky, K. Kian Ang - New England Journal of Medicine 2006 cited by 5,106

  4. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

    Authors: Charu Aggarwal, Jeffrey C. Thompson, Taylor A. Black, Sharyn I. Katz, Ryan Fan, Stephanie S. Yee, Austin L. Chien, Tracey L. Evans, Joshua Bauml, Evan Alley, Christine Ciunci, Abigail T. Berman, Roger B. Cohen, David Lieberman, Krishna S. Majmundar, Samantha L. Savitch, Jennifer J.D. Morrissette, Wei‐Ting Hwang, Kojo S.J. Elenitoba‐Johnson, Corey J. Langer, Erica L. Carpenter - JAMA Oncology 2018 cited by 490

  5. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

    Authors: Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain P. Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen - Journal of Clinical Oncology 2017 cited by 471

  6. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

    Authors: Charu Aggarwal, Amy Prawira, Scott Antonia, Osama E. Rahma, Anthony W. Tolcher, Roger B. Cohen, Yanyan Lou, Ralph J. Hauke, Nicholas J. Vogelzang, Dan P. Zandberg, Arash Rezazadeh Kalebasty, Victoria Atkinson, Alex A. Adjei, ­Mahesh Seetharam, Ariel E. Birnbaum, Andrew Weickhardt, Vinod Ganju, Anthony M. Joshua, Rosetta Cavallo, Linda Peng, Xiaoyu Zhang, Sanjeev Kaul, Jan Baughman, Ezio Bonvini, Paul A. Moore, S. Goldberg, Fernanda I. Arnaldez, Robert L. Ferris, Nehal J. Lakhani - Journal for ImmunoTherapy of Cancer 2022 cited by 141

  7. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer

    Authors: Lova Sun, Benjamin Aaron Bleiberg, Wei‐Ting Hwang, Melina E. Marmarelis, Corey J. Langer, Aditi P. Singh, Roger B. Cohen, Ronac Mamtani, Charu Aggarwal - JAMA Oncology 2023 cited by 148

  8. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

    Authors: James A. Bonner, Paul M. Harari, J. Giralt, Roger B. Cohen, Christopher U. Jones, Ranjan Sur, David Raben, José Baselga, Sharon A. Spencer, Junming Zhu, Hagop Youssoufian, Eric K. Rowinsky, K. Kian Ang - The Lancet Oncology 2009 cited by 1,974

  9. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

    Authors: Jeffrey C. Thompson, Erica L. Carpenter, Benjamin A. Silva, J Rosenstein, Austin L. Chien, Katie Quinn, Carin R. Espenschied, Allysia J. Mak, Lesli A. Kiedrowski, Martina I. Lefterova, Rebecca J. Nagy, Sharyn I. Katz, Stephanie S. Yee, Taylor A. Black, Aditi P. Singh, Christine Ciunci, Joshua Bauml, Roger B. Cohen, Corey J. Langer, Charu Aggarwal - JCO Precision Oncology 2021 cited by 105

  10. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

    Authors: Stephen Bagley, Shawn Kothari, Charu Aggarwal, Joshua Bauml, Evan Alley, Tracey L. Evans, John A. Kosteva, Christine Ciunci, Peter Gabriel, Jeffrey C. Thompson, Susan Stonehouse-Lee, Victoria Sherry, Elizabeth Gilbert, Beth Eaby‐Sandy, Faith Mutale, Gloria A DiLullo, Roger B. Cohen, Anil Vachani, Corey J. Langer - Lung Cancer 2017 cited by 529

  11. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer

    Authors: Joshua Bauml, Rosemarie Mick, Christine Ciunci, Charu Aggarwal, Christiana Davis, Tracey L. Evans, Charuhas Deshpande, Linda Miller, Pooja Patel, Evan Alley, Christina Knepley, Faith Mutale, Roger B. Cohen, Corey J. Langer - JAMA Oncology 2019 cited by 320

  12. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

    Authors: Bert H. O’Neil, John M. Wallmark, David Lorente, Élena Elez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina A. Piha‐Paul, Mark N. Stein, Albiruni R. Abdul Razak, Katia Dotti, Armando Santoro, Roger B. Cohen, M. Gould, Sanatan Saraf, Karen Stein, Sae‐Won Han - PLoS ONE 2017 cited by 305

  13. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer

    Authors: Marshall R. Posner, Diáne Hershock, C. Blajman, E. Mickiewicz, Eric Winquist, Vera Gorbounova, Sergei Tjulandin, Dong M. Shin, Kevin J. Cullen, Thomas J. Ervin, Barbara A. Murphy, Luis E. Raez, Roger B. Cohen, Monica B. Spaulding, Roy B. Tishler, Berta Roth, Rosana del Carmen Viroglio, Varagur Venkatesan, И. С. Романов, Sanjiv S. Agarwala, K. William Harter, Matthew Dugan, Anthony J. Cmelak, Arnold M. Markoe, Paul W. Read, Lynn M. Steinbrenner, A. Dimitrios Colevas, Charles M. Norris, Robert I. Haddad - New England Journal of Medicine 2007 cited by 1,704

  14. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

    Authors: Julie K. Jadlowsky, Elizabeth O. Hexner, Amy Marshall, Stephan A. Grupp, Noelle V. Frey, James L. Riley, Elizabeth Veloso, Holly McConville, Walter Rogal, Cory Czuczman, Wei‐Ting Hwang, Yimei Li, Rachel Leskowitz, Olivia Farrelly, Jayashree Karar, Shannon Christensen, Julie S. Barber-Rotenberg, Avery L. Gaymon, Naomi Aronson, Wendy Bernstein, J. Joseph Melenhorst, Aoife M. Roche, J.K. Everett, Sonja A. Zolnoski, Alexander McFarland, Shantan Reddy, Angelina Petrichenko, Emma J. Cook, Carole Lee, Vanessa Gonzalez, Kathleen A. Alexander, Irina Kulikovskaya, Ángel Ramírez-Fernández, Janna Minehart, Marco Ruella, Saar Gill, Stephen J. Schuster, Adam D. Cohen, Alfred L. Garfall, Payal D. Shah, David L. Porter, Shannon L. Maude, Bruce L. Levine, Don L. Siegel, Anne Chew, S.J. McKenna, Lester Lledo, Megan M. Davis, Gabriela Plesa, Friederike Herbst, Edward A. Stadtmauer, Pablo Tebas, Amanda M. DiNofia, A. Haas, Naomi B. Haas, Regina M. Myers, Donald M. O’Rourke, Jakub Svoboda, János L. Tanyi, Richard Aplenc, Jeffrey M. Jacobson, Andrew H. Ko, Roger B. Cohen, Carl H. June, Frederic D. Bushman, Joseph A. Fraietta - Nature Medicine 2025 cited by 71

  15. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

    Authors: Roger B. Cohen, Jean‐Pierre Delord, Toshihiko Doi, Sarina A. Piha‐Paul, Stephen V. Liu, Jill Gilbert, Alain P. Algazi, Silvia Damian, Ruey‐Long Hong, Christophe Le Tourneau, Daphne Day, Andréa Varga, Elena Élez, John M. Wallmark, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam - American Journal of Clinical Oncology 2018 cited by 206

  16. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

    Authors: Charu Aggarwal, Melina E. Marmarelis, Wei‐Ting Hwang, Dylan Scholes, Tara McWilliams, Aditi P. Singh, Lova Sun, John A. Kosteva, Michael R. Costello, Roger B. Cohen, Corey J. Langer, Abigail Doucette, Peter Gabriel, Lawrence N. Shulman, Katharine A. Rendle, Jeffrey C. Thompson, Justin E. Bekelman, Erica L. Carpenter - JCO Precision Oncology 2023 cited by 44

  17. 854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)

    Authors: Jérôme Fayette, Lisa Licitra, Kevin J. Harrington, Robert I. Haddad, Lillian L. Siu, Yi‐Chun Liu, Makoto Tahara, J-P. Machiels, Danny Rischin, Tanguy Y. Seiwert, Robert L. Ferris, Ulrich Keilholz, Amanda Psyrri, Bhumsuk Keam, Paolo Bossi, Robert Metcalf, Oscar K. Serrano, Paramjit Kaur, Dario Ruscica, Roger B. Cohen - Annals of Oncology 2023 cited by 32

  18. A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus–Related Squamous Cell Carcinoma of the Oropharynx

    Authors: Samuel Swisher‐McClure, John N. Lukens, Charu Aggarwal, Peter H. Ahn, Devraj Basu, Joshua Bauml, Robert M. Brody, Ara A. Chalian, Roger B. Cohen, Alireza Fotouhi-Ghiam, Geoffrey A. Geiger, Jared Gershowitz, Virginia A. LiVolsi, Nandita Mitra, Kathleen T. Montone, Jason G. Newman, Eric Ojerholm, Bert W. O’Malley, Karthik Rajasekaran, Erik X. Tan, Gregory S. Weinstein, Alexander Lin - International Journal of Radiation Oncology*Biology*Physics 2019 cited by 170

  19. Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

    Authors: Charu Aggarwal, Jeffrey C. Thompson, Austin L. Chien, Katie Quinn, Wei‐Ting Hwang, Taylor A. Black, Stephanie S. Yee, Theresa Christensen, Michael J. LaRiviere, Benjamin A. Silva, Kimberly C. Banks, Rebecca J. Nagy, Elena Helman, Abigail T. Berman, Christine Ciunci, Aditi P. Singh, Jeffrey S. Wasser, Joshua Bauml, Corey J. Langer, Roger B. Cohen, Erica L. Carpenter - Clinical Cancer Research 2020 cited by 103

  20. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors

    Authors: Jeffrey R. Infante, E. Claire Dees, Anthony J. Olszanski, Shyeilla V. Dhuria, Suman Sen, Scott B. Cameron, Roger B. Cohen - Journal of Clinical Oncology 2014 cited by 209

  21. Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

    Authors: Lova Sun, Miles Hsu, Roger B. Cohen, Corey J. Langer, Ronac Mamtani, Charu Aggarwal - JAMA Oncology 2021 cited by 85

  22. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

    Authors: Razelle Kurzrock, Steven I. Sherman, Douglas W. Ball, Arlene A. Forastiere, Roger B. Cohen, Ranee Mehra, David G. Pfister, Ezra E.W. Cohen, Linda Janisch, Forlisa Nauling, David S. Hong, Chaan S. Ng, Lei Ye, Robert F. Gagel, John Frye, Thomas Müller, Mark J. Ratain, Ravi Salgia - Journal of Clinical Oncology 2011 cited by 551

  23. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

    Authors: Jeffrey C. Thompson, Stephanie S. Yee, Andrea B. Troxel, Samantha L. Savitch, Ryan Fan, David Balli, David Lieberman, Jennifer D. Morrissette, Tracey L. Evans, Joshua Bauml, Charu Aggarwal, John A. Kosteva, Evan Alley, Christine Ciunci, Roger B. Cohen, Stephen Bagley, Susan Stonehouse-Lee, Victoria Sherry, Elizabeth Gilbert, Corey J. Langer, Anil Vachani, Erica L. Carpenter - Clinical Cancer Research 2016 cited by 328

  24. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer

    Authors: Charu Aggarwal, Roger B. Cohen, Matthew P. Morrow, Kimberly A. Kraynyak, Albert J. Sylvester, Dawson Knoblock, Joshua Bauml, Gregory S. Weinstein, Alexander Lin, Jean Boyer, Lindsay Sakata, Sophie Seine Xuan Tan, Aubrey Anton, Kelsie Dickerson, Drishty Mangrolia, Russell Vang, Michael Dallas, Sandra Oyola, Susan Duff, Mark T. Esser, Rakesh Kumar, David B. Weiner, Ildiko Csiki, Mark L. Bagarazzi - Clinical Cancer Research 2018 cited by 144